

MYRIAD
myPlan[™]
Lung Cancer



A whole new measure of your cancer

myPlan[™] Lung Cancer will give you and your doctor additional information about the aggressiveness of your early-stage lung adenocarcinoma that no other test can.

An increasingly common diagnosis

Lung cancer is now one of the most common cancers diagnosed in the United States. However, compared with other common cancers, such as breast and colon cancer, lung cancer carries a higher risk of mortality.

No two cancers are the same

A diagnosis of early-stage non-small cell lung adenocarcinoma is alarming. So, it's important to know that all lung cancer tumors are not the same. With myPlan Lung Cancer, you now have the ability to learn more about the aggressiveness of your specific tumor—so you and your doctor can make the most informed decision about your individual treatment plan.

Lung cancer stage might not tell the whole story

You most likely know the stage of your lung cancer. Your cancer stage classification is based primarily on the size and location of your tumor—or how far your cancer has progressed. But your cancer stage does not reveal the “aggressiveness” of your disease. Since cancer is the uncontrolled, rapid growth of abnormal cells, an aggressive tumor carries the potential risk of growing and spreading more rapidly.

myPlan Lung Cancer provides a new measure

myPlan Lung Cancer provides a measure of the aggressiveness of 46 of your individual cancer genes. Because not all early-stage lung adenocarcinomas are the same, getting a myPlan Lung Cancer Prognostic Score will give you and your doctor additional information about the aggressiveness of your cancer that no other test can.

What is myPlan Lung Cancer?

myPlan Lung Cancer is a measure of how fast the cells in your tumor are dividing. Since you have already had a tumor resection, that same tissue sample can be used to determine your myPlan Lung Cancer Prognostic Score. Studies have shown that myPlan Lung Cancer provides an accurate assessment of cancer aggressiveness.^{1,2} And, because every individual's lung cancer is different, the result of your myPlan Lung Cancer test is unique to you.

myPlan clarifies short-term risk

Two patients with the same lung cancer stage may have a very different estimate of mortality risk when their myPlan Lung Cancer Prognostic Score is included in their evaluation.



Your cancer. Your personalized treatment plan

Your myPlan Lung Cancer Prognostic Score provides unique information that can help you and your doctor make the best treatment decision for you. For example, if you have an early-stage lung adenocarcinoma and a low Prognostic Score, you and your doctor may choose a less aggressive treatment plan. On the other hand, if your Prognostic Score reveals a more aggressive cancer, you and your doctor may choose to treat your cancer with an equally aggressive therapy.

After receiving test results, you and your doctor will decide your course of treatment. The added information from the myPlan Lung Cancer test can allow you to have more confidence in the decisions made about your medical care.

myPlan Lung Cancer helps to make more informed decisions

- Provides unique insight into a cancer's relative aggressiveness
- Helps in determining your course of treatment
- Gives you and your doctor more confidence in treatment decisions

For more information, please contact Myriad at:

lung@myriad.com
or call 800.231.4447

You can also visit us online at:

myplanlungcancer.com

REFERENCES

1. Wistuba II, Behrens C, Lombardi F, et al. Prognostic Marker in EarlyStage Lung Adenocarcinoma. *Clinical Cancer Research*. September 18, 2013. [Epub ahead of print].
2. Whitfield ML, Sherlock G, Saldanha AJ, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. *Mol Biol Cell*. 2002;13:1977-2000.



Myriad Genetic Laboratories, Inc.
320 Wakara Way
Salt Lake City, UT 84108-9930
E-mail: lung@myriad.com

MYRIAD®

Myriad, the Myriad logo, Myriad MyPlan and the Myriad MyPlan logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions.

© 2013 Myriad Genetic Laboratories, Inc.

MPLPTBR/08-13